Khalil Hanan, Hoppe Dimi, Ameen Nabil
Department of Public Health, La Trobe University, Melbourne, Vic 3000, Australia.
Diploma of Management, Master of Advanced Health Care Practice, School of Public Health, La Trobe University, Melbourne, Vic, Australia.
Ther Adv Drug Saf. 2021 May 29;12:20420986211012854. doi: 10.1177/20420986211012854. eCollection 2021.
Retrospective analyses of large databases of treated patients can provide useful links to the presence of drug misuse or rare and infrequent adverse effects, such as agranulocytosis, diabetic ketoacidosis or neuroleptic malignant syndrome. The aim of this study is to describe the adverse effects to antipsychotics reported in the Australian Database of Adverse Event Notifications (DAEN).
Data were collected from the DAEN - a spontaneous reporting database. The database, which covered the period from January 2004 to December 2017, was obtained from the Therapeutic Goods Administration (TGA) website (www.TGA.gov). The drugs selected for this investigation are the following: aripiprazole, clozapine, olanzapine, paliperidone, risperidone, ziprasidone, quetiapine, haloperidol and pimozide. All data were analysed descriptively. Comparison of reporting and management of adverse events between adults (older than 20 years) and children (5-19 years) was undertaken using chi squared test, where < 0.05 is significant.
A total of 7122 adverse events associated with the antipsychotics aripiprazole, clozapine, haloperidol, olanzapine, paliperidone, pimozide, quetiapine and risperidone were reported to the TGA between January 2004 and December 2017. On average, there were 2.6 adverse events reported for each case. The most common adverse event reported for antipsychotics was neuroleptic malignant syndrome. There were no significant differences in the number of co-medications, formulations, indications, therapeutic dose, hospital admission and overdose among the antipsychotics between paediatric and adult populations. However, there were significant differences between causality, death and the management of adverse events between adult and paediatric populations (5-19 years) ( < 0.05, chi squared test).
The antipsychotic drug associated with the highest adverse events in adults was clozapine, followed by olanzapine. The most common adverse event in adults, and reported with a number of antipsychotic drugs, was neuroleptic malignant syndrome. In children, the highest numbers of adverse events reported in the database were associated with risperidone, clozapine and olanzapine.
Adverse events reported of antipsychotics Retrospective analyses of large databases of treated patients can provide useful clues to the presence of drug misuse or rare and infrequent adverse effects associated with antipsychotics. The drugs selected for this investigation are the following: aripiprazole, clozapine, olanzapine, paliperidone, risperidone, ziprasidone, quetiapine, haloperidol and pimozide. All data were analysed descriptively and investigated for any associations between the variables collected. Comparison of reporting and management of adverse events between adults (older than 20 years) and children (5-19 years) was undertaken using chi squared test, where < 0.05 is significant. The antipsychotic drug associated with the highest adverse events was clozapine, followed by olanzapine. In children, the highest numbers of adverse events reported in the database were associated with risperidone, clozapine and olanzapine. The most common adverse event in adults, and reported with a number of antipsychotic drugs, was neuroleptic malignant syndrome. There were significant differences between causality, death and the management of adverse events between adult and paediatric populations (5-19 years).Keywords: Antipsychotics, adverse effects, adverse events, safety.
对大量接受治疗患者的数据库进行回顾性分析,可为药物滥用或罕见及不常见不良反应(如粒细胞缺乏症、糖尿病酮症酸中毒或抗精神病药恶性综合征)的存在提供有用线索。本研究的目的是描述澳大利亚不良事件通知数据库(DAEN)中报告的抗精神病药物不良反应。
数据收集自DAEN——一个自发报告数据库。该数据库涵盖2004年1月至2017年12月期间,从治疗用品管理局(TGA)网站(www.TGA.gov)获取。本研究选择的药物如下:阿立哌唑、氯氮平、奥氮平、帕利哌酮、利培酮、齐拉西酮、喹硫平、氟哌啶醇和匹莫齐特。所有数据均进行描述性分析。采用卡方检验对成人(20岁以上)和儿童(5 - 19岁)之间不良事件的报告和管理情况进行比较,其中P < 0.05具有统计学意义。
2004年1月至2017年12月期间,TGA共收到7122例与抗精神病药物阿立哌唑、氯氮平、氟哌啶醇、奥氮平、帕利哌酮、匹莫齐特、喹硫平和利培酮相关的不良事件报告。平均而言,每例报告2.6例不良事件。抗精神病药物报告的最常见不良事件是抗精神病药恶性综合征。儿科和成人人群在联合用药数量、剂型、适应证、治疗剂量、住院和过量用药方面,抗精神病药物之间无显著差异。然而,成人和儿科人群(5 - 19岁)在因果关系、死亡和不良事件管理方面存在显著差异(卡方检验,P < 0.05)。
成人中与不良事件发生率最高相关的抗精神病药物是氯氮平,其次是奥氮平。成人中最常见的不良事件,且多种抗精神病药物均有报告,是抗精神病药恶性综合征。在儿童中,数据库中报告不良事件数量最多的与利培酮、氯氮平和奥氮平有关。
抗精神病药物的不良事件报告 对大量接受治疗患者的数据库进行回顾性分析,可为抗精神病药物滥用或罕见及不常见不良反应的存在提供有用线索。本研究选择的药物如下:阿立哌唑、氯氮平、奥氮平、帕利哌酮、利培酮、齐拉西酮、喹硫平、氟哌啶醇和匹莫齐特。所有数据均进行描述性分析,并对收集的变量之间的任何关联进行研究。采用卡方检验对成人(20岁以上)和儿童(5 - 19岁)之间不良事件的报告和管理情况进行比较,其中P < 0.05具有统计学意义。与不良事件发生率最高相关的抗精神病药物是氯氮平,其次是奥氮平。在儿童中,数据库中报告不良事件数量最多的与利培酮、氯氮平和奥氮平有关。成人中最常见的不良事件,且多种抗精神病药物均有报告,是抗精神病药恶性综合征。成人和儿科人群(5 - 19岁)在因果关系、死亡和不良事件管理方面存在显著差异。关键词:抗精神病药物、不良反应、不良事件、安全性